Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 9171
Country/Region: Kenya
Year: 2015
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $12,841,756 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,317,462
Care: Orphans and Vulnerable Children (HKID) $830,154
Care: TB/HIV (HVTB) $422,894
Care: Pediatric Care and Support (PDCS) $460,088
Laboratory Infrastructure (HLAB) $1,538,063
Strategic Information (HVSI) $540,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $1,018,048
Sexual Prevention: Abstinence/Be Faithful (HVAB) $40,220
Prevention: HIV Testing and Counseling (HVCT) $1,697,762
Sexual Prevention: Other Sexual Prevention (HVOP) $507,530
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $700
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,349,716
Treatment: Adult Treatment (HTXS) $3,059,477
Treatment: Pediatric Treatment (PDTX) $59,642
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR_DSD Age/sex: 1-4 Female 2016 441
CARE_CURR_DSD Age/sex: 1-4 Male 2016 446
CARE_CURR_DSD Age/sex: 10-14 Female 2016 619
CARE_CURR_DSD Age/sex: 10-14 Male 2016 589
CARE_CURR_DSD Age/sex: 15-19 Female 2016 552
CARE_CURR_DSD Age/sex: 15-19 Male 2016 309
CARE_CURR_DSD Age/sex: 20-24 Female 2016 2,219
CARE_CURR_DSD Age/sex: 20-24 Male 2016 573
CARE_CURR_DSD Age/sex: 25-49 Female 2016 18,411
CARE_CURR_DSD Age/sex: 25-49 Male 2016 8,061
CARE_CURR_DSD Age/sex: 5-9 Female 2016 800
CARE_CURR_DSD Age/sex: 5-9 Male 2016 745
CARE_CURR_DSD Age/sex: 50+ Female 2016 3,609
CARE_CURR_DSD Age/sex: 50+ Male 2016 2,826
CARE_CURR_DSD Age/sex: <1 Female 2016 70
CARE_CURR_DSD Age/sex: <1 Male 2016 61
CARE_CURR_DSD Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 40,484
CARE_CURR_DSD Sum of Age/Sex disaggregates 2016 40,331
CARE_NEW_DSD Age/sex: 1-4 Female 2016 119
CARE_NEW_DSD Age/sex: 1-4 Male 2016 153
CARE_NEW_DSD Age/sex: 10-14 Female 2016 182
CARE_NEW_DSD Age/sex: 10-14 Male 2016 162
CARE_NEW_DSD Age/sex: 15-19 Female 2016 172
CARE_NEW_DSD Age/sex: 15-19 Male 2016 102
CARE_NEW_DSD Age/sex: 20-24 Female 2016 622
CARE_NEW_DSD Age/sex: 20-24 Male 2016 150
CARE_NEW_DSD Age/sex: 25-49 Female 2016 4,954
CARE_NEW_DSD Age/sex: 25-49 Male 2016 2,185
CARE_NEW_DSD Age/sex: 5-9 Female 2016 256
CARE_NEW_DSD Age/sex: 5-9 Male 2016 218
CARE_NEW_DSD Age/sex: 50+ Female 2016 1,006
CARE_NEW_DSD Age/sex: 50+ Male 2016 834
CARE_NEW_DSD Age/sex: <1 Female 2016 31
CARE_NEW_DSD Age/sex: <1 Male 2016 14
CARE_NEW_DSD Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 11,563
CARE_NEW_DSD Sum of Age/sex disaggregates 2016 11,160
FN_THER_DSD Age: 1-4 2016 113
FN_THER_DSD Age: 15-17 2016 142
FN_THER_DSD Age: 18+ 2016 4,821
FN_THER_DSD Age: 5-14 2016 383
FN_THER_DSD Age: <1 2016 14
FN_THER_DSD Aggregated Age: 18+ 2016 3,594
FN_THER_DSD Aggregated Age: <18 2016 454
FN_THER_DSD Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 5,940
FN_THER_DSD Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2016 5,884
FN_THER_DSD Sum of Age disaggregates 2016 5,473
FN_THER_DSD Sum of Aggregated Age disaggregates 2016 4,048
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 227,934
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 227,656
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 40,012
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 40,194
HTC_TST_DSD By Test Result: Negative 2016 79
HTC_TST_DSD By Test Result: Positive 2016 2
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 567,274
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2016 455,590
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2016 80,206
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2016 535,796
HTC_TST_DSD Sum of Test Result disaggregates 2016 81
KP_PREV_DSD By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2016 9,002
KP_PREV_DSD Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2016 9,260
OVC_SERV_DSD Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2016 13,553
PMTCT_ARV_DSD Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2016 661
PMTCT_ARV_DSD Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 2,896
PMTCT_ARV_DSD Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 2,896
PMTCT_ARV_DSD Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 1,201
PMTCT_ARV_DSD Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 877
PMTCT_ARV_DSD Sum of New and Current disaggregates 2016 2,078
PMTCT_ARV_DSD Sum of Regimen Type disaggregates 2016 757
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2016 1,119
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2016 1,076
PMTCT_EID_DSD Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 2,195
PMTCT_EID_DSD Sum of Infant Age disaggregates 2016 2,195
PMTCT_STAT_DSD By: Known positives at entry 2016 10,500
PMTCT_STAT_DSD By: Number of new positives identified 2016 10,697
PMTCT_STAT_DSD Number of new ANC and L&D clients 2016 121,755
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 120,342
PMTCT_STAT_DSD Sum of Positives Status disaggregates 2016 21,197
TB_ART_DSD Aggregated Age: 15+ 2016 11
TB_ART_DSD Aggregated Age: <15 2016 6
TB_ART_DSD Female 2016 476
TB_ART_DSD Known HIV-positive 2016 388
TB_ART_DSD Male 2016 517
TB_ART_DSD Sum of Aggregated Age disaggregates 2016 17
TB_ART_DSD Sum of Sex disaggregates 2016 993
TB_ART_DSD Sum of Test Status disaggregates 2016 388
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 997
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 997
TB_SCREEN_DSD Age: 1-4 2016 870
TB_SCREEN_DSD Age: 10-14 2016 1,354
TB_SCREEN_DSD Age: 15-19 2016 1,172
TB_SCREEN_DSD Age: 5-9 2016 1,532
TB_SCREEN_DSD Age: <1 2016 120
TB_SCREEN_DSD Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2016 45
TB_SCREEN_DSD Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2016 25
TB_SCREEN_DSD Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 40,484
TB_SCREEN_DSD Sex: Female 2016 25,423
TB_SCREEN_DSD Sex: Male 2016 14,780
TB_SCREEN_DSD Sum of Age disaggregates 2016 40,203
TB_SCREEN_DSD Sum of Aggregated Age disaggregates 2016 70
TB_SCREEN_DSD Sum of Sex disaggregates 2016 40,203
TB_SCREEN_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 40,207
TX_CURR_DSD Age/Sex: 1-4 Female 2016 406
TX_CURR_DSD Age/Sex: 1-4 Male 2016 418
TX_CURR_DSD Age/Sex: 5-14 Female 2016 982
TX_CURR_DSD Age/Sex: 5-14 Male 2016 903
TX_CURR_DSD Age/Sex: <1 Female 2016 50
TX_CURR_DSD Age/Sex: <1 Male 2016 46
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2016 4,706
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2016 2,214
TX_CURR_DSD Aggregated Age/Sex: <1 Female 2016 11
TX_CURR_DSD Aggregated Age/Sex: <1 Male 2016 11
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2016 37,364
TX_CURR_DSD Sum of age/sex disaggregates 2016 37,084
TX_CURR_DSD Sum of Aggregated Age/Sex (<1 and 1-14) <15 2016 697
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2016 6,920
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2016 6,920
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2016 1,500
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2016 706
TX_NEW_DSD Aggregated Grouping by Age/Sex: <1 Female 2016 4
TX_NEW_DSD Aggregated Grouping by Age: <1 Male 2016 4
TX_NEW_DSD By Age/Sex: 1-4 Female 2016 105
TX_NEW_DSD By Age/Sex: 1-4 Male 2016 105
TX_NEW_DSD By Age/Sex: 10-14 Female 2016 147
TX_NEW_DSD By Age/Sex: 10-14 Male 2016 144
TX_NEW_DSD By Age/Sex: 15-19 Female 2016 137
TX_NEW_DSD By Age/Sex: 15-19 Male 2016 85
TX_NEW_DSD By Age/Sex: 20-24 Female 2016 619
TX_NEW_DSD By Age/Sex: 20-24 Male 2016 191
TX_NEW_DSD By Age/Sex: 25-49 Female 2016 4,612
TX_NEW_DSD By Age/Sex: 25-49 Male 2016 2,025
TX_NEW_DSD By Age/Sex: 5-9 Female 2016 193
TX_NEW_DSD By Age/Sex: 5-9 Male 2016 178
TX_NEW_DSD By Age/Sex: 50+ Female 2016 886
TX_NEW_DSD By Age/Sex: 50+ Male 2016 713
TX_NEW_DSD By Age/Sex: <1 Female 2016 10
TX_NEW_DSD By Age/Sex: <1 Male 2016 9
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 10,180
TX_NEW_DSD Sum of Age/Sex disaggregates 2016 10,159
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2016 2,206
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 5,336
TX_RET_DSD Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at months after initiating ART) 2016 2,812
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 5,595
VMMC_CIRC_DSD By Age: 10-14 2016 3,121
VMMC_CIRC_DSD By Age: 15-19 2016 4,160
VMMC_CIRC_DSD By Age: 20-24 2016 3,789
VMMC_CIRC_DSD By Age: 50+ 2016 74
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2016 15,906
VMMC_CIRC_DSD By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2016 11,453
VMMC_CIRC_DSD By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2016 67
VMMC_CIRC_DSD By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2016 15,789
VMMC_CIRC_DSD By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2016 50
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 15,906
VMMC_CIRC_DSD Sum of age disaggregates 2016 11,144
Cross Cutting Budget Categories and Known Amounts Total: $283,000
Human Resources for Health $25,000
Food and Nutrition: Policy, Tools, and Service Delivery $10,000
Food and Nutrition: Commodities $25,000
Education $18,000
Key Populations: FSW $150,000
Monitoring and evaluation of SW programs
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: Gender Equality $5,000
Equity in HIV prevention, care, treatment and support
Implementation
Condoms: Policy, Tools, and Services $50,000